Dapivirine is an experimental non-nucleoside reverse transcriptase inhibitor. A gel formulation of dapivirine is now being investigated as a vaginal microbicide.
The nonprofit International Partnership for Microbicides is pleased to announce the World Health Organization's prequalification of the dapivirine ring, a monthly vaginal ring to reduce women's HIV risk.
The development of safe and effective HIV prevention methods for cisgender women has long been a global health priority, yet research in women during pregnancy and breastfeeding, when they are most vulnerable to infection, has lagged years behind.
The International Partnership for Microbicides today welcomed a positive opinion from the European Medicines Agency on the dapivirine vaginal ring for use by cisgender women ages 18 and older in developing countries to reduce their risk of HIV-1 infection.
A vaginal ring intended to be used for a month at a time has moved one step closer to potentially becoming a new HIV prevention method for cisgender women in sub-Saharan Africa, who despite being the face of the epidemic, have few options for protecting themselves against getting infected.
A woman who is eight-months pregnant is the first participant to be enrolled into a study evaluating the safety and acceptability of two different HIV prevention approaches when used during pregnancy -- the monthly dapivirine vaginal ring, which is currently under regulatory review, and a daily antiretroviral (ARV) pill called Truvada, an approach already approved in several countries and commonly referred to as PrEP, short for pre-exposure prophylaxis.
The first clinical trial specifically designed to test the safety of the monthly dapivirine vaginal ring in pregnant women has begun in southern and eastern Africa.
In an open-label study of women in southern and eastern Africa, a vaginal ring that is inserted once a month and slowly releases an antiviral drug was estimated to reduce the risk of HIV by 39%, according to statistical modeling.
A clinical trial has begun to examine the safety and use of two HIV prevention tools--oral pre-exposure prophylaxis and a vaginal ring--in adolescent girls and young women in southern Africa.
AIDS is already the leading cause of death among girls and young women in much of Africa, and matters could only get worse, given that for every day that passes, 1,000 more girls ages 15 to 24 are likely to become infected with HIV.
The nonprofit International Partnership for Microbicides announced today the start of the first clinical trial of vaginal rings designed to slowly release the antiretroviral drug dapivirine over three months to prevent HIV in women.
The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults.
Most women who used an experimental vaginal ring for HIV prevention report that the physical act of sex was largely unaffected by using the product, which is inserted monthly for continuous wear.
Women who took part in ASPIRE, a trial that found a vaginal ring containing an antiretroviral (ARV) drug called dapivirine was safe and helped protect against HIV, will soon be offered the opportunity to use the ring as part of a new study called HOPE.
In an important scientific achievement for women's health, two large Phase III clinical trials -- The Ring Study and ASPIRE -- have shown that a monthly vaginal ring containing the antiretroviral drug (ARV) dapivirine can safely help prevent HIV-1 infection in women.
In a first for HIV prevention, an international team of researchers have completed follow-up of participants enrolled in a pivotal Phase III trial that tested the safety and effectiveness of a vaginal ring for preventing HIV in women.
ASPIRE, one of two Phase III trials of a promising method for preventing HIV in women - a vaginal ring worn for a month at a time - has completed enrollment of participants, with 2,629 women from 15 clinical research sites in Malawi, South Africa, Uganda and Zimbabwe now taking part in the study.
The International Partnership for Microbicides announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.
Findings of an early phase clinical trial at the University of Alabama at Birmingham suggest that a possible new method of protecting women from the transmission of HIV is safe.
Two early clinical studies of novel HIV prevention products for women - the first combination antiretroviral (ARV) vaginal ring and a vaginal film - show the products to be safe and open the door to product improvements that could expand options for women-initiated prevention tools. The results of both studies were presented today at the 21st Conference on Retroviruses and Opportunistic Infections.